NEW YORK, Sept. 8 (GenomeWeb News) - Linden Bioscience has signed a deal to provide its Tilia oligonucloetide probe design service to Dutch biotech firm PamGene International, the companies said today.

PamGene plans to use the probes with its 5D-Pulse microarray platform, which is the basis for the company's FD10 system and soon-to-be launched PamStation 96 microarray system.

Specific terms of the arrangement were not disclosed.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

NPR reports that with medical data being big business, some companies want to get patients involved.

The Asbury Park Press reports on the startup Genomic Prediction's test to determine an embryo's risk of disease.

In PNAS this week: optical mapping allows glimpse of structural variants, disease-linked GATA2 mutations boosts its protein activity, and more.

Senator Elizabeth Warren (D-Mass.) has released the results of a genetic ancestry analysis, the Boston Globe reports.